|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Loibl S, Poortmans P, Morrow M, Denkert C
and Curigliano G: Breast cancer. Lancet. 397:1750–1769. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Urbaniak A, Piña-Oviedo S, Yuan Y,
Huczyński A and Chambers TC: Limitations of an ex vivo breast
cancer model for studying the mechanism of action of the anticancer
drug paclitaxel. Eur J Pharmacol. 891:1737802021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dranitsaris G, King J, Kaura S, Yu B and
Zhang A: Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in
metastatic breast cancer: A cost-utility analysis from a Chinese
health care perspective. Clinicoecon Outcomes Res. 7:249–256. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gradishar WJ: Albumin-bound paclitaxel: A
next-generation taxane. Expert Opin Pharmacother. 7:1041–1053.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gradishar WJ, Tjulandin S, Davidson N,
Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J: Phase III
trial of nanoparticle albumin-bound paclitaxel compared with
polyethylated castor oil-based paclitaxel in women with breast
cancer. J Clin Oncol. 23:7794–7803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee H, Park S, Kang JE, Lee HM, Kim SA and
Rhie SJ: Efficacy and safety of nanoparticle-albumin-bound
paclitaxel compared with solvent-based taxanes for metastatic
breast cancer: A meta-analysis. Sci Rep. 10:5302020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aapro M, Tjulandin S, Bhar P and Gradishar
W: Weekly nab-paclitaxel is safe and effective in ≥65 years old
patients with metastatic breast cancer: A post-hoc analysis.
Breast. 20:468–474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Megerdichian C, Olimpiadi Y and Hurvitz
SA: Nab-paclitaxel in combination with biologically targeted agents
for early and metastatic breast cancer. Cancer Treat Rev.
40:614–625. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Untch M, Jackisch C, Schneeweiss A, Conrad
B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S,
Hilfrich J, et al: Nab-paclitaxel versus solvent-based paclitaxel
in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG
69): A randomised, phase 3 trial. Lancet Oncol. 17:345–356. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guidelines of Chinese Society of Clinical
Oncology(CSCO)-Breast Cancer2024, . 2024.www.csco.org.cn
|
|
13
|
Breast Tumours WHO Classification of
Tumours, . 2019.www.iarc.who.int
|
|
14
|
NCCN Clinical Practice Guidelines in
Oncology-Breast Cancer, . 2024.www.nccn.org/patients
|
|
15
|
Allison KH, Hammond MEH, Dowsett M,
McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR,
Chavez-MacGregor M, Perlmutter J, et al: Estrogen and progesterone
receptor testing in breast cancer: American society of clinical
Oncology/College of American Pathologists Guideline update. Arch
Pathol Lab Med. 144:545–563. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wolff AC, Somerfield MR, Dowsett M,
Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA and
Allison KH: Human epidermal growth factor receptor 2 testing in
breast cancer: ASCO-college of American Pathologists Guideline
update. J Clin Oncol. 41:3867–3872. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Common Terminology Criteria for Adverse
Events (CTCAE)v5.0, . 2017.ctep.cancer.gov
|
|
18
|
Li B, Chen X, Ding T, Liu Y, Ma T, Zhang G
and Wang X: Nanoparticle albumin-bound paclitaxel versus
solvent-based paclitaxel in breast cancer. Medicine.
100:e245142021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Burstein1 HJ, Curigliano G, Loibl S,
Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C,
Piccart-Gebhart M, Regan M, et al: Estimating the benefits of
therapy for early-stage breast cancer: The St. Gallen International
Consensus Guidelines for the primary therapy of early breast cancer
2019. Ann Oncol. 30:1541–1557. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yardley D, Burris H, Peacock N, Raefsky E,
Melnik M, Inhorn R, Shipley D and Hainsworth J: A pilot study of
adjuvant nanoparticle albumin-bound (nab) paclitaxel and
cyclophosphamide, with trastuzumab in HER2-positive patients, in
the treatment of early-stage breast cancer. Breast Cancer Res
Treat. 123:471–475. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li BX, Chen XJ, Ding TJ, Liu YH, Ma TT,
Zhang GL and Wang XM: Potentially overestimated efficacy of
nanoparticle Albumin-bound paclitaxel compared with Solvent-based
paclitaxel in breast cancer: A systemic review and Meta-analysis. J
Cancer. 12:5164–5172. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cho E, Wu Q, Rubinstein L, Linden H,
Gralow J, Specht J, Gadi V and Ellis G: Adjuvant continuous
metronomic adriamycin + cyclophosphamide followed by weekly
nab-paclitaxel for high-risk early-stage breast cancer. Breast J.
24:610–614. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
von Minckwitz G, Conrad B, Reimer T,
Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marmé F,
Potenberg J, et al: A randomized phase 2 study comparing EC or CMF
versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy
for nonfrail elderly patients with moderate to high-risk early
breast cancer (ICE II-GBG 52). Cancer. 121:3639–3648. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pedersen RN, Esen BÖ, Mellemkjær L,
Christiansen P, Ejlertsen B, Lash TL, Nørgaard M and Cronin-Fenton
D: The incidence of breast cancer recurrence 10–32 years after
primary diagnosis. J Natl Cancer Inst. 114:391–399. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schoen MW, Chen J, Tu Y, Mohammed KA,
Rodin MB and Hinyard LJ: Diabetes outcomes in patients with breast
cancer. J Clin Oncol. 36:e220782018. View Article : Google Scholar
|
|
26
|
Zhao XB and Ren GS: Diabetes mellitus and
prognosis in women with breast cancer: A systematic review and
meta-analysis. Medicine. 95:e56022016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chou PC, Choi HH, Huang Y, Fuentes-Mattei
E, Velazquez-Torres G, Zhang F, Phan L, Lee J, Shi Y, Bankson JA,
et al: Impact of diabetes on promoting the growth of breast cancer.
Cancer Commun (Lond). 41:414–431. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Calip GS, Elmore JG and Boudreau DM:
Characteristics associated with nonadherence to medications for
hypertension, diabetes, and dyslipidemia among breast cancer
survivors. Breast Cancer Res Treat. 161:161–172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
He F, Liu J, Shen X, Wang Z, Li Q and Li
G: Adverse event profile for nanoparticle albumin-bound paclitaxel
compared with solvent-based taxanes in solid-organ tumors: A
systematic review and meta-analysis of randomized clinical trials.
Ann Pharmacother. 56:898–909. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brufsky A: Nab-paclitaxel for the
treatment of breast cancer: An update across treatment settings.
Exp Hematol Oncol. 6:72017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bi Z, Chen P, Liu YB, Zhao T, Sun X, Song
XR and Wang YS: Efficacy and safety analysis of paclitaxel,
docetaxel and liposomal paclitaxel after neoadjuvant therapy in
breast cancer. Breast Cancer Res Treat. 184:397–405. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Elleson KM, Englander K, Gallagher J,
Chintapally N, Sun W, Whiting J, Mallory M, Kiluk J, Hoover S,
Khakpour N, et al: Factors predictive of positive lymph nodes for
breast cancer. Curr Oncol. 30:10351–10362. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Anwar SL, Cahyono R, Prabowo D, Avanti WS,
Choridah L, Dwianingsih EK, Harahap WA and Aryandono T: Metabolic
comorbidities and the association with risks of recurrent
metastatic disease in breast cancer survivors. BMC Cancer. 21:1–13.
2021. View Article : Google Scholar : PubMed/NCBI
|
